Hyperbaric Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Senior Clinical Lecturer, University of Queensland, Brisbane, Australia.
Diving Hyperb Med. 2021 Mar 31;51(1):68-71. doi: 10.28920/dhm51.1.68-71.
Idiopathic sudden sensorineural hearing loss (ISSHL) is an otolaryngologic emergency. The Undersea and Hyperbaric Medicine Society (UHMS) revised practice guidelines in 2014 adding ISSHL to approved indications. This study investigated whether the UHMS guidelines influenced referral and practice in Australia and New Zealand.
Retrospective review of 319 patient referrals in two time periods (five years prior to addition of ISSHL to indications (T-PRE) and three years post (T-POST)).
Seven of eight participating hyperbaric facilities provided data down to the level of the indication for HBOT for analysis. In T-PRE 136 patients were treated with HBOT for ISSHL, representing between 0% and 18% of the total cases to each facility. In the T-POST period 183 patients were treated for ISSHL, representing from 0.35% to 24.8% of the total patients in each facility. Comparison between the two periods shows the proportion of patients treated with ISSHL among all indications increased from 3.2% to 12.1% (P < 0.0009). One facility accounted for 74% (101/136) of ISSHL patients receiving HBOT in T-PRE and 63% (116/183) in T-POST. ISSHL case load at that facility increased from 18% to 24.8% (P = 0.009) after the UHMS guideline publication. Three of the seven units had a significant increase in referrals after the guideline change.
There remains equipoise regarding HBOT in the management of ISSHL. Only three out of seven units had a significant increase in ISSHL patients after the UHMS guidelines publication. Without well controlled RCTs to develop guidelines based on good evidence this is unlikely to change and practice variation will continue.
特发性突发性聋(ISSHL)是一种耳鼻喉科急症。2014 年,深海和高压医学学会(UHMS)修订了实践指南,将 ISSHL 纳入了批准的适应证。本研究调查了 UHMS 指南是否影响了澳大利亚和新西兰的转诊和实践。
对两个时间段(在将 ISSHL 添加到适应证(T-PRE)之前的五年和之后的三年(T-POST))的 319 例患者转诊进行回顾性分析。
八个参与高压氧治疗设施中的七个提供了用于 HBOT 适应证分析的详细数据。在 T-PRE 中,136 例患者因 ISSHL 接受 HBOT 治疗,占每个设施总病例数的 0%至 18%。在 T-POST 期间,183 例患者因 ISSHL 接受治疗,占每个设施总患者数的 0.35%至 24.8%。两个时期之间的比较表明,所有适应证中接受 ISSHL 治疗的患者比例从 3.2%增加到 12.1%(P<0.0009)。在 T-PRE 中,1 家机构收治了 74%(101/136)的 ISSHL 患者接受 HBOT,在 T-POST 中收治了 63%(116/183)。在 UHMS 指南发布后,该机构的 ISSHL 病例数从 18%增加到 24.8%(P=0.009)。指南改变后,7 个单位中有 3 个单位的转诊量显著增加。
HBOT 在 ISSHL 的治疗中仍存在争议。UHMS 指南发布后,只有 7 个单位中的 3 个单位的 ISSHL 患者显著增加。由于缺乏基于良好证据的、经过良好对照的 RCT 来制定指南,这种情况不太可能改变,实践差异将继续存在。